Literature DB >> 19521694

Can we get the necessary clinical trials in children and avoid the unnecessary ones?

Kalle Hoppu.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19521694     DOI： 10.1007/s00228-009-0675-y

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN： 0031-6970            Impact factor:   2.953


× No keyword cloud information.
  5 in total

1.  Depressing research.

Authors: 
Journal:  Lancet       Date:  2004-04-24       Impact factor: 79.321

2.  Paediatric clinical pharmacology: at the beginning of a new era.

Authors:  Kalle Hoppu
Journal:  Eur J Clin Pharmacol       Date:  2007-10-31       Impact factor: 2.953

3.  Children and tuberculosis medicines: bridging the research gap.

Authors:  Suzanne Hill; Ilaria Regondi; Malgorzata Grzemska; Robert Matiru
Journal:  Bull World Health Organ       Date:  2008-09       Impact factor: 9.408

4.  Off-label use of medicines in children: can available evidence avoid useless paediatric trials? The case of proton pump inhibitors for the treatment of gastroesophageal reflux disease.

Authors:  Giovanni Tafuri; Francesco Trotta; Hubert G M Leufkens; Nello Martini; Luciano Sagliocca; Giuseppe Traversa
Journal:  Eur J Clin Pharmacol       Date:  2008-09-17       Impact factor: 2.953

5.  Knowledge of developmental pharmacology and modeling approaches should be used to avoid useless trials in children.

Authors:  Saskia N de Wildt; Catherijne A J Knibbe
Journal:  Eur J Clin Pharmacol       Date:  2009-04-25       Impact factor: 2.953
  5 in total
  3 in total

1.  Development of a physiologically based model for oseltamivir and simulation of pharmacokinetics in neonates and infants.

Authors:  Neil Parrott; Brian Davies; Gerhard Hoffmann; Annette Koerner; Thierry Lave; Eric Prinssen; Elizabeth Theogaraj; Thomas Singer
Journal:  Clin Pharmacokinet       Date:  2011-09       Impact factor: 6.447

Review 2.  Clinical trials in children.

Authors:  Pathma D Joseph; Jonathan C Craig; Patrina H Y Caldwell
Journal:  Br J Clin Pharmacol       Date:  2015-03       Impact factor: 4.335

Review 3.  Ocular medicines in children: the regulatory situation related to clinical research.

Authors:  Filomena Fortinguerra; Antonio Clavenna; Maurizio Bonati
Journal:  BMC Pediatr       Date:  2012-01-20       Impact factor: 2.125
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.